In South Korea, liver transplantation (LT) began in 1988 when the first deceased donor liver transplantation (DDLT) of a child with Wilson’s disease was successful. Then, in 1994, living donor liver transplantation (LDLT) was first attempted in the country. In 1999, the Korean Network for Organ Sharing (KONOS) was established as the national institution to carry out transplant-related tasks, such as organ allocation. Since 2002, the model for endstage liver disease (MELD) score has been used as a criterion for long-term distribution in many regions around the world, including the USA and Europe. In South Korea, the allocation system for emergency LT has been based on the MELD score since June 2016.
Since the 2010s, the DDLT rate has continuously increased, accounting for more than 20% of all liver transplants and 34.5% of all liver transplants in 2016. However, the amount of DDLT decreased again in 2017, with its proportion accounting for 25% of the total LT cases. In 2019, the number of brain-death organ donors in South Korea was 8.7 per million people. This was much lower than the 49.6 per million people in Spain and the 36.1 per million people in the USA, and also far less than the 20 or more per million people reported in France, UK, and Australia [
1]. Due to the shortage of brain-death donors in South Korea, DDLT is being performed with an average MELD score as high as 36.5 points. Since DDLT is performed when the MELD score is too high, there is a concern that the number of cases with poor prognosis after DDLT may increase. Therefore, LT in South Korea, as in other East Asian countries, has been largely dependent on LDLT amid a shortage of brain-death donors.
A common indication for LT is an acute or chronic liver disease in which liver function is deteriorated severely to a point where it does not respond to any other treatments and can only be treated with a LT. Liver cirrhosis caused by viral hepatitis (hepatitis B or C) or alcohol, autoimmune hepatitis, primary sclerosing cholangitis, biliary atresia, Wilson’s disease, and hepatocellular carcinoma (HCC) are chronic liver diseases requiring LT. Due to the development of surgical technique, postoperative care, and expansion of LDLT, the indications for LT are gradually expanding. However, LT is still contraindicated in patients with severe heart and lung diseases, extrahepatic malignancy, and uncontrolled sepsis.
Hepatitis B and herbal medicine are the most common causes of acute liver failure requiring LT in South Korea [
2]. Until 2000, the incidence of acute hepatitis A has declined; but after that, the number of hepatitis A-induced fulminant liver failure patients increased as the hepatitis A antibody-positive rate decreased in younger people under 30 years of age.
For chronic liver disease, in the past, more than 70% of adult LTs in South Korea were performed for cirrhosis and/or HCC caused by the hepatitis B virus. However, in recent years, this proportion has decreased due to the development of antiviral agents. The proportion of patients receiving LT for liver cirrhosis or HCC due to hepatitis C has been increasing; however, after treatment with direct acting antiviral agents (DAA) in 2014, the proportion has declined again. On the other hand, as viral hepatitis has decreased, the number of LT for alcoholic liver disease has been increasing. Also, similar to other countries, South Korea has been seeing a steady rise in the number of LT for nonalcoholic steatohepatitis or nonalcoholic fatty liver disease. Moreover, the number of patients receiving LT as a treatment for HCC has gradually increased as LDLT is being actively implemented in South Korea [
3].
Recently, the 1-year survival rate of DDLT has reached 77.9%, and the 1-year survival rate of LDLT has reached 89.9%. The 1-year survival rate of all LT is reported to be good enough to reach 86.9% due to improved surgical technique and patient management, as well as the appropriate use of various immunosuppressants. In addition, postoperative mortality is directly related to the severity of LT recipients; therefore, it is important to prepare for transplantation in a timely manner [
4]. The 3-year and 5-year survival rates in South Korea have been excellent, reaching 83.7% and 80.9% for LDLT and 72.3% and 68.9% for DDLT, respectively (total, 80.8% and 77.9%, respectively). The long-term survival rate after LT in South Korea is also excellent, and the 10-year survival rate after transplantation has reached 70%, which is comparable to the 10-year survival rate of 63% in other countries [
4,
5].
The survival rate of LT in patients with HCC may vary depending on the size and number of tumors, as well as tumor biology. So far, LT has shown the best survival rate among the currently available treatment methods for HCC. However, LT for HCC patients still have problems that need to be addressed, including donor shortage and ethical issues. This is because LT in HCC is almost entirely dependent on LDLT. Liver resection for living donor is a procedure that requires high degree of surgical skills, with its mortality rate reported to be 0.2–0.5% in foreign countries [
6]. In South Korea, one in 7,000 donors died after surgery. In addition, minimally invasive surgery, such as laparoscopic or robotic surgery, is being more actively performed for donor hepatectomy in South Korea than in any other country. This minimally invasive surgery helps donors to recover earlier.
FOOTNOTES
-
Conflicts of Interest
The author has no conflicts to disclose.
Abbreviations
direct acting antiviral agents
deceased donor liver transplantation
Korean Network for Organ Sharing
living donor liver transplantation
model for end-stage liver disease
REFERENCES
- 1. Joo DJ. Current status of deceased donor liver transplantation for alcoholic liver disease in Korea in MELD era. Korean J Gastroenterol 2021;77:4-11.
- 2. Jin YJ, Lim YS, Han S, Lee HC, Hwang S, Lee SG. Predicting survival after living and deceased donor liver transplantation in adult patients with acute liver failure. J Gastroenterol 2012;47:1115-1124.
- 3. Korean Network for Organ Sharing (KONOS). 2019 Annual report of organ and tissue donation and transplantation. KONOS web site, <https://www.konos.go.kr/konosis/common/bizlogic.jsp>. Accessed 1 Dec 2020.
- 4. Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg 2013;258:409-421.
- 5. Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol 2013;10:434-440.
- 6. Shiffman ML, Brown RS Jr, Olthoff KM, Everson G, Miller C, Siegler M, et al. Living donor liver transplantation: summary of a conference at The National Institutes of Health. Liver Transpl 2002;8:174-188.
Citations
Citations to this article as recorded by
- Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
Journal of Korean Medical Science.2026;[Epub] CrossRef - Hemodynamic Profile, Clinical Outcomes, and Potential Transplant Candidacy in Patients With Portopulmonary Hypertension
Soongu Kwak, Yechan Kim, Doyeon Hwang, Ki Hong Choi, Jeehoon Kang, Jeong Hoon Yang, Hyung-Kwan Kim, Sung-A Chang
Korean Circulation Journal.2026;[Epub] CrossRef - Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure
Kunhee Kim, Seung Hyuk Yim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Jun Yong Park, Sang Hoon Ahn, Deok‐Gie Kim, Hye Won Lee
Alimentary Pharmacology & Therapeutics.2025; 61(1): 168. CrossRef - Impact of Chronic Hepatitis C Virus on Acute Kidney Injury After Living Donor Liver Transplantation
Jae Hwan Kim, Kyoung-Sun Kim, Hye-Mee Kwon, Sung-Hoon Kim, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
Anesthesia & Analgesia.2025; 141(3): 608. CrossRef - Appropriate timing and interval for surveillance colonoscopy after liver transplantation based on a single-centre experience
Dae Gon Ryu, Hongqun Liu, Samuel S Lee, Ki Tae Yoon, Mayur Brahmania
Canadian Liver Journal.2025; 8(1): 39. CrossRef - Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef - Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e161. CrossRef - Emergency living donor liver transplantation
Jongman Kim
Annals of Liver Transplantation.2025; 5(1): 27. CrossRef - Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation
Young Jin Yoo, Deok-Gie Kim, Eun-Ki Min, Seung Hyuk Yim, Mun Chae Choi, Hwa-Hee Koh, Minyu Kang, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo
Transplant International.2025;[Epub] CrossRef - Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 107. CrossRef - Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 115. CrossRef - Liver Transplantation at a Small Volume Center—The Role of Network System
Chang Ho Seo, Ho Joong Choi, Gun Hyung Na
Transplantation Proceedings.2024; 56(3): 653. CrossRef - Approach to Liver Transplantation: Is There a Difference between East and West?
Nazli Begum Ozturk, Nathanial Bartosek, Merih Deniz Toruner, Aymen Mumtaz, Cem Simsek, Doan Dao, Behnam Saberi, Ahmet Gurakar
Journal of Clinical Medicine.2024; 13(7): 1890. CrossRef - Anastomosis selection in liver transplantation for recipients with unusable recipient hepatic arteries: a bayesian network meta-analysis
Warsinggih, Citra Aryanti, Julianus Aboyaman Uwuratuw, Erwin Syarifuddin, Ronald Erasio Lusikooy, Muhammad Faruk
BMC Surgery.2024;[Epub] CrossRef - Mortality and associated factors among patients who underwent liver transplantation in South Korea from 2017 to 2021: a retrospective observational study
Tak Kyu Oh, In-Ae Song
Annals of Surgical Treatment and Research.2024; 107(5): 245. CrossRef - Chronological improvements of living donor liver transplantation for hepatocellular carcinoma in Seoul National University Hospital
Saran Ochir Gongor, Kwang-Woong Lee, Nam-Joon Yi, YoungRok Choi, Suk Kyun Hong, Jeong-Moo Lee, Jae-Yoon Kim, Kyung-Suk Suh
Annals of Liver Transplantation.2024; 4(2): 71. CrossRef - Outcomes of living donor liver transplantation in patients with concurrent extrahepatic malignancy
John Hee Park, Jongman Kim, Sunghyo An, Namkee Oh, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Annals of Liver Transplantation.2024; 4(2): 102. CrossRef - How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clinical and Molecular Hepatology.2023; 29(2): 411. CrossRef - Validation of MELD 3.0 scoring system in East Asian patients with cirrhosis awaiting liver transplantation
Jeong-Ju Yoo, Jong-In Chang, Ji Eun Moon, Dong Hyun Sinn, Sang Gyune Kim, Young Seok Kim
Liver Transplantation.2023; 29(10): 1029. CrossRef - Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef - The Effect of Model for End-Stage Liver Disease 3.0 on Disparities between Patients with and without Hepatocellular Carcinoma in Korea
Kunhee Kim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Hye Won Lee
Yonsei Medical Journal.2023; 64(11): 647. CrossRef - Comparison of Fibrinogen Concentrate and Cryoprecipitate on Major Thromboembolic Events after Living Donor Liver Transplantation
Jae-Hwan Kim, Kyoung-Sun Kim, Hye-Mee Kwon, Sung-Hoon Kim, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
Journal of Clinical Medicine.2023; 12(23): 7496. CrossRef - The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report
Incheon Kang, Jae-myeong Lee, Jae Geun Lee
Korean Journal of Transplantation.2022; 36(4): 294. CrossRef
